Fedratinib | SAR 302503 | JAK2 Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Fedratinib

Fedratinib {[allProObj[0].p_purity_real_show]}

货号：A345883 同义名： SAR 302503;TG 101348

Fedratinib（TG-101348）是一种强效、选择性、ATP竞争性和口服活性的JAK2抑制剂，对JAK2和JAK2V617F激酶的IC50值均为3 nM。菲达替尼相对于JAK1和JAK3显示出35倍和334倍的选择性。它诱导癌细胞凋亡，并具有潜在的骨髓增殖性疾病研究价值。

Fedratinib 化学结构
CAS号：936091-26-8

Fedratinib 3D分子结构
CAS号：936091-26-8

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Fedratinib 纯度/质量文件产品仅供科研

货号：A345883 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell, 2024, 101755. Ambeed. [ A399663 ]; • EMBO J., 2024. Ambeed. [ A295334 ]; • JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]; • JMC, 2024. Ambeed. [ A210558 , A1518164 ]; • Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]; 更多 >

c-RET 亚型比较
JAK 亚型比较
FLT3 亚型比较

产品名称	c-RET ↓ ↑	其他靶点	纯度
Regorafenib	+++ RET, IC50: 1.5 nM		98%
TG101209	++ RET, IC50: 17 nM	FLT3	99%+
Danusertib	+ RET, IC50: 31 nM		99%+
AD80	++++ RET V804M, IC50: 0.6 nM RET wt, IC50: 1.3 nM	Src,Raf	99+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	JAK1 ↓ ↑	JAK2 ↓ ↑	JAK3 ↓ ↑	Tyk2 ↓ ↑	其他靶点	纯度
Decernotinib	+++ JAK1, Ki: 11 nM JAK1, IC50: 11 nM	+++ JAK2, Ki: 13 nM	++++ JAK3, Ki: 2.5 nM	+++ TYK2, Ki: 13 nM		99%+
ZM39923 HCl	+ JAK1, pIC50: 4.4		+ JAK3, pIC50: 7.1		EGFR	97%
Cerdulatinib	+++ JAK1, IC50: 12 nM	+++ JAK2, IC50: 6 nM	+++ JAK3, IC50: 8 nM	++++ TYK2, IC50: 0.5 nM		99%+
Momelotinib	+++ JAK1, IC50: 11 nM	++ JAK2, IC50: 18 nM	+ JAK3, IC50: 155 nM			99%+
XL019	+ JAK1, IC50: 134.3 nM	++++ JAK2, IC50: 2.2 nM	+ JAK3, IC50: 214.2 nM		FLT3	99%+
Ruxolitinib	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM				98%
Tofacitinib	+ JAK1, IC50: 112 nM	++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			98%
Ruxolitinib (S enantiomer)	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM		++ TYK2, IC50: 19 nM		98%
Filgotinib	+++ JAK1, IC50: 10 nM	++ JAK2, IC50: 28 nM	+ JAK3, IC50: 810 nM	+ TYK2, IC50: 116 nM		99%
Baricitinib	+++ JAK1, IC50: 5.9 nM	+++ JAK2, IC50: 5.7 nM		++ TYK2, IC50: 53 nM		99%
Gandotinib	++ JAK1, IC50: 19.8 nM	++++ JAK2, IC50: 0.288 nM JAK2 (V617F), Ki: 0.245 nM	++ JAK3, IC50: 48.0 nM	++ TYK2, IC50: 44 nM	FLT3	99%+
Oclacitinib maleate	+++ JAK1, IC50: 10nM	++ JAK2, IC50: 18nM	+ JAK3, IC50: 99nM	+ TYK2, IC50: 84nM		98+%
NVP-BSK805 2HCl	++ JAK1, IC50: 31.63 nM	++++ JAK2, IC50: ~0.5 nM	++ JAK3, IC50: 18.68 nM	+++ TYK2, IC50: 10.76 nM		99+%
Peficitinib		✔				98%
Go6976		✔			FLT3	99%+
AZD-1480		++++ JAK2, IC50: 0.26 nM				99%+
Fedratinib		+++ JAK2 (V617F), IC50: 3 nM JAK2, IC50: 3 nM			FLT3,RET	99%+
WP1066		+ JAK2, IC50: 2.3 μM				98%
Curcumol		✔				98%
AZ960		++++ JAK2, Ki: 0.45 nM JAK2, IC50: <3 nM				97%
GLPG0634 analog		✔				99%+
CEP-33779		++++ JAK2, IC50: 1.8 nM				99%+
FLLL32		+ JAK2, IC50: <5 μM				99%+
WHI-P154			+ JAK3, IC50: 1.8 μM		EGFR,Src,VEGFR	98%
BMS-911543		++++ JAK2, IC50: 1.1 nM	+ JAK3, IC50: 75 nM	++ TYK2, IC50: 66 nM		98%
TG101209		+++ JAK2, IC50: 6 nM	+ JAK3, IC50: 169 nM		FLT3,RET	99%+
AT9283		++++ JAK2, IC50: 1.2 nM	++++ JAK3, IC50: 1.1 nM			99%+
Pacritinib		++ JAK2 (V617F), IC50: 19 nM JAK2, IC50: 23 nM	+ JAK3, IC50: 520 nM	++ TYK2, IC50: 50 nM	FLT3	97%
Tofacitinib citrate		++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			99%
FM-381			++++ JAK3, IC50: 127 pM			98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	FLT3 ↓ ↑	其他靶点	纯度
R406	✔	Syk	98%
Go6976	✔		99%+
Quizartinib	+++ FLT3 (ITD), IC50: 1.1 nM FLT3 (WT), IC50: 4.2 nM		98%
Gilteritinib	++++ FLT3, IC50: 0.29 nM		99%+
Amuvatinib	+ FLT3 (D835Y), IC50: 81 nM		99%+
Pacritinib	++ FLT3 (D835Y), IC50: 6 nM FLT3, IC50: 22 nM		97%
Dovitinib	++++ FLT3, IC50: 1 nM	c-Kit	99%+
Denfivontinib	++++ FLT3 (D835Y), IC50: 0.4 nM FLT3, IC50: 0.4 nM	RET	99%+
TAK-659 HCl	++ FLT3, IC50: 4.6 nM	Syk	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Fedratinib 生物活性

靶点

JAK2

JAK2 (V617F), IC50:3 nM

JAK2, IC50:3 nM

描述

Fedratinib is a selective JAK2 inhibitor with IC50 values of 3nM, 3nM, 15nM and 48nM for JAK2, JAK2 V617F, Flt3 and Ret, respectively. Fedratinib inhibited proliferation of a human erythroblast leukemia (HEL) cell line that harbors the JAK2V617F mutation, as well as a murine pro-B cell line expressing human JAK2V617F (Ba/F3 JAK2V617F), with an IC50 value of approximately 300nM for either line. Exposure of these cells to Fedratinib reduced STAT5 phosphorylation at concentrations that parallel the concentrations required to inhibit cell proliferation. Also it induced apoptosis in both HEL and Ba/F3 JAK2V617F cells in a dose-dependent manner. It showed therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation. It triggered a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis^[2].

Fedratinib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
Ba/F3 JAK2V617F		Growth Inhibition Assay		IC50=270 nM	18394554
Bcr-abl		Growth Inhibition Assay		IC50=2.7 (2.2–3.3) μM	24251790
Caco-2	0-120 μM	Function Assay	7 min	inhibits thiamine uptake with an IC50 of 2.1 µM	25063672
Caco-2	10/50/100 μM	Function Assay	2 h	decreases the flux of [3H]thiamine across the monolayer with IC50 of 6.5 μM	25063672

Fedratinib 动物研究

Dose	Mice: 1 g/kg^[2] (p.o.), 30 mg/kg - 200 mg/kg^[1] (p.o.) Rat: 2 mg/kg^[3] (i.v.)
Administration	p.o., i.v.

Fedratinib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01437787	Hematopoietic Neoplasm	Phase 3	Completed	-	-
NCT01585623	Solid Tumor	Phase 1	Completed	-	United States, Georgia ... 展开 >> Investigational Site Number 840004 Augusta, Georgia, United States, 30912 United States, Michigan Investigational Site Number 840001 Detroit, Michigan, United States, 48201 United States, Pennsylvania Investigational Site Number 840002 Philadelphia, Pennsylvania, United States, 19111 收起 <<
NCT01836705	Neoplasm Malignant	Phase 1	Completed	-	United States, California ... 展开 >> Investigational Site Number 840003 Los Angeles, California, United States, 90048 United States, Georgia Investigational Site Number 840007 Augusta, Georgia, United States, 30912 United States, Michigan Investigational Site Number 840002 Detroit, Michigan, United States, 48201 United States, Missouri Investigational Site Number 840001 St Louis, Missouri, United States, 63110 United States, Ohio Investigational Site Number 840004 Cincinnati, Ohio, United States, 45267-0542 United States, Pennsylvania Investigational Site Number 840005 Philadelphia, Pennsylvania, United States, 19111 United States, Texas Investigational Site Number 840006 San Antonio, Texas, United States, 78229 Investigational Site Number 840008 San Antonio, Texas, United States, 78229 Belgium Investigational Site Number 056001 Bruxelles, Belgium, 1200 Investigational Site Number 056002 Gent, Belgium, 9000 收起 <<

Fedratinib 参考文献

[1]Wernig G, Kharas MG, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20.

[2]Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. doi: 10.1016/j.ccr.2008.02.009. PMID: 18394554.

Fedratinib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.53mL

1.91mL

0.95mL

19.06mL

3.81mL

1.91mL

Fedratinib 技术信息

CAS号	936091-26-8
分子式	C₂₇H₃₆N₆O₃S
分子量	524.678

别名	SAR 302503;TG 101348
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

溶解度

DMSO: 120 mg/mL(228.71 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

Ba/F3 JAK2V617F		Growth Inhibition Assay		IC50=270 nM	18394554
Bcr-abl		Growth Inhibition Assay		IC50=2.7 (2.2–3.3) μM	24251790
Caco-2	0-120 μM	Function Assay	7 min	inhibits thiamine uptake with an IC50 of 2.1 µM	25063672
Caco-2	10/50/100 μM	Function Assay	2 h	decreases the flux of [3H]thiamine across the monolayer with IC50 of 6.5 μM	25063672
CD4+ T	0.01-1 μM	Function Assay	48 h	reduces the phosphorylation levels of JAK2 and STAT3	25572535
FE-PD	0.063-4 μM	Growth Inhibition Assay		IC50=9.5 μM, inhibits cell growth dose dependently	23372669
H1650	0.5-2 μM	Apoptosis Assay	12-48 h	induces apoptosis in both dose- and time- dependent manner	25869210
H1650	0.25-1 μM	Function Assay	24 h	inhibits expression of apoptosis-related protein Bcl-XL, Bcl-2, survivin, XIAP	25869210
H1650	1 μM	Growth Inhibition Assay	48 h	sensitizes cells to the cytotoxicity of erlotinib	25869210
H1975	0.5-2 μM	Apoptosis Assay	12-48 h	induces apoptosis in both dose- and time- dependent manner	25869210
H1975	0.25-1 μM	Function Assay	24 h	inhibits expression of apoptosis-related protein Bcl-XL, Bcl-2, survivin, XIAP	25869210
H1975	1 μM	Growth Inhibition Assay	48 h	sensitizes cells to the cytotoxicity of erlotinib	25869210
HDLM2	0-5 μM	Growth Inhibition Assay	48 h	inhibits cell growth significantly	24610827
HDLM2	0/0.625/1.25 μM	Apoptosis Assay	48 h	induces the apoptosis	24610827
HDLM2	0-5 μM	Function Assay	24 h	inhibits JAK2/STAT signaling	24610827
HEK293 MSR	0-10 μM	Function Assay	7 min	inhibits hTHTR2 with an IC50 of 1.2 µM	25063672
HEL	0.063-4 μM	Growth Inhibition Assay		IC50=1.5 μM, inhibits cell growth dose dependently	23372669
HEL		Growth Inhibition Assay		IC50=305 nM	18394554
JAK2 TW		Growth Inhibition Assay		IC50=1.8 (1.5–2.3) μM	24251790
JAK2 V617F		Growth Inhibition Assay		IC50=0.6 (0.6–0.7) μM	24251790
K1106	1/2 μM	Function Assay	24 h	decreases STAT6 phosphorylation concentration dependently	24977668
K1106	4 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth time dependently	23852366
K1106P	0-5 μM	Growth Inhibition Assay	48 h	inhibits cell growth significantly	24610827
K1106P	0/0.625/1.25 μM	Apoptosis Assay	48 h	induces the apoptosis	24610827
K1106P	0-5 μM	Function Assay	24 h	inhibits JAK2/STAT signaling	24610827
K562	0-1 μM	Growth Inhibition Assay	72 h	inhibits K562 cell proliferation at high concentration	24775308
K-562	0.063-4 μM	Growth Inhibition Assay		IC50=2.5 μM, inhibits cell growth dose dependently	23372669
KMH2	0-5 μM	Growth Inhibition Assay	48 h	inhibits cell growth significantly	24610827
KMH2	0/0.625/1.25 μM	Apoptosis Assay	48 h	induces the apoptosis	24610827
KMH2	0-5 μM	Function Assay	24 h	inhibits JAK2/STAT signaling	24610827
L1236	0-5 μM	Growth Inhibition Assay	48 h	inhibits cell growth significantly	24610827
L1236	0/0.625/1.25 μM	Apoptosis Assay	48 h	induces the apoptosis	24610827
L1236	0-5 μM	Function Assay	24 h	inhibits JAK2/STAT signaling	24610827
L428	0-5 μM	Growth Inhibition Assay	48 h	inhibits cell growth significantly	24610827
L428	0/0.625/1.25 μM	Apoptosis Assay	48 h	induces the apoptosis	24610827
L428	0-5 μM	Function Assay	24 h	inhibits JAK2/STAT signaling	24610827
L-82	0.063-4 μM	Growth Inhibition Assay		IC50=0.98 μM, inhibits cell growth dose dependently	23372669
MAC-1	0.063-4 μM	Growth Inhibition Assay		IC50=0.52 μM, inhibits cell growth dose dependently	23372669
MAC-2A	0.063-4 μM	Growth Inhibition Assay		IC50=0.69 μM, inhibits cell growth dose dependently	23372669
MAC-2B	0.063-4 μM	Growth Inhibition Assay		IC50=0.54 μM, inhibits cell growth dose dependently	23372669
MDA-MB-468	3 µM	Growth Inhibition Assay	48 h	enhanced sibcl6 induced loss of cell viability	24662818
MDA-MB-468	0-4 μM	Growth Inhibition Assay	48 h	results significant loss of viability compared to RI-BPI alone	24662818
MedB-1	1/2 μM	Function Assay	24 h	decreases STAT6 phosphorylation concentration dependently	24977668
MedB-1	4 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth time dependently	23852366
MM.1S		Growth Inhibition Assay		IC50=1-3 μM	24584101
M-MOK	25 µM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth time dependently	21853157
MY-LA	0.063-4 μM	Growth Inhibition Assay		IC50=2.1 μM, inhibits cell growth dose dependently	23372669
NC-NC	0.063-4 μM	Growth Inhibition Assay		IC50=1.0 μM, inhibits cell growth dose dependently	23372669
SE-AX	0.063-4 μM	Growth Inhibition Assay		IC50=1.5 μM, inhibits cell growth dose dependently	23372669
SR-786	0.063-4 μM	Growth Inhibition Assay		IC50=4.6 μM, inhibits cell growth dose dependently	23372669
SUPHD1	0-5 μM	Growth Inhibition Assay	48 h	inhibits cell growth significantly	24610827
SUPHD1	0/0.625/1.25 μM	Apoptosis Assay	48 h	induces the apoptosis	24610827
SUPHD1	0-5 μM	Function Assay	24 h	inhibits JAK2/STAT signaling	24610827
TpoR JAK2 V617F		Growth Inhibition Assay		IC50=0.8 (0.7–0.9) μM	24251790
TpoR JAK2 WT		Growth Inhibition Assay		IC50=1.4 (1.3–1.5) μM	24251790
TpoR W515L		Growth Inhibition Assay		IC50=0.8 (0.7–1.0) μM	24251790
U2940	1/2 μM	Function Assay	24 h	decreases STAT6 phosphorylation concentration dependently	24977668
U2940	4 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth time dependently	23852366

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01437787	Hematopoietic Neoplasm	Phase 3	Completed	-	-
NCT01585623	Solid Tumor	Phase 1	Completed	-	United States, Georgia ... 展开 >> Investigational Site Number 840004 Augusta, Georgia, United States, 30912 United States, Michigan Investigational Site Number 840001 Detroit, Michigan, United States, 48201 United States, Pennsylvania Investigational Site Number 840002 Philadelphia, Pennsylvania, United States, 19111 收起 <<
NCT01836705	Neoplasm Malignant	Phase 1	Completed	-	United States, California ... 展开 >> Investigational Site Number 840003 Los Angeles, California, United States, 90048 United States, Georgia Investigational Site Number 840007 Augusta, Georgia, United States, 30912 United States, Michigan Investigational Site Number 840002 Detroit, Michigan, United States, 48201 United States, Missouri Investigational Site Number 840001 St Louis, Missouri, United States, 63110 United States, Ohio Investigational Site Number 840004 Cincinnati, Ohio, United States, 45267-0542 United States, Pennsylvania Investigational Site Number 840005 Philadelphia, Pennsylvania, United States, 19111 United States, Texas Investigational Site Number 840006 San Antonio, Texas, United States, 78229 Investigational Site Number 840008 San Antonio, Texas, United States, 78229 Belgium Investigational Site Number 056001 Bruxelles, Belgium, 1200 Investigational Site Number 056002 Gent, Belgium, 9000 收起 <<
NCT01420770	Hematopoietic Neoplasm	Phase 2	Completed	-	United States, California ... 展开 >> Investigational Site Number 840001 San Francisco, California, United States, 94143 United States, Michigan Investigational Site Number 840003 Ann Arbor, Michigan, United States, 48109-0759 United States, Minnesota Investigational Site Number 840006 Rochester, Minnesota, United States, 55905 United States, Ohio Investigational Site Number 840007 Canton, Ohio, United States, 44718 收起 <<
NCT01692366	Myelofibrosis	Phase 2	Completed	-	Japan ... 展开 >> Investigational Site Number 392010 Akita-Shi, Japan Investigational Site Number 392002 Bunkyo-Ku, Japan Investigational Site Number 392006 Bunkyo-Ku, Japan Investigational Site Number 392004 Sendai-Shi, Japan Investigational Site Number 392008 Shinjuku-Ku, Japan Investigational Site Number 392009 Shinjuku-Ku, Japan Investigational Site Number 392003 Suita-Shi, Japan 收起 <<
NCT01420783	Hematopoietic Neoplasm	Phase 2	Completed	-	-
NCT03723148	-		-	-	United States, New Jersey ... 展开 >> Celgene Summit, New Jersey, United States, 07901 收起 <<
NCT00724334	Myelofibrosis	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> Investigational Site Number 840103 La Jolla, California, United States, 92093 Investigational Site Number 840102 Stanford, California, United States, 94305 United States, Massachusetts Investigational Site Number 840105 Boston, Massachusetts, United States, 02115 United States, Michigan Investigational Site Number 840106 Ann Arbor, Michigan, United States, 48109-0759 United States, Minnesota Investigational Site Number 840104 Rochester, Minnesota, United States, 55905 United States, Texas Investigational Site Number 840101 Houston, Texas, United States, 77030 收起 <<
NCT02596347	-		Unknown	-	United States, Colorado ... 展开 >> National Jewish Health Recruiting Denver, Colorado, United States, 80206 Contact: Gina M Atnes, BA 303-398-1679 mondellog@njhealth.org Principal Investigator: Li Li, MD 收起 <<
NCT01763190	Renal Impairment	Phase 1	Completed	-	United States, Florida ... 展开 >> Investigational Site Number 840002 Orlando, Florida, United States, 32809 United States, Minnesota Investigational Site Number 840003 St. Paul, Minnesota, United States, 55144 United States, Tennessee Investigational Site Number 840001 Knoxville, Tennessee, United States, 37920 收起 <<
NCT01762462	Hepatic Impairment	Phase 1	Completed	-	United States, Florida ... 展开 >> Investigational Site Number 840003 Miami, Florida, United States, 33014 Investigational Site Number 840002 Orlando, Florida, United States, 32809 United States, Tennessee Investigational Site Number 840001 Knoxville, Tennessee, United States, 37920 收起 <<
NCT01523171	Hematopoietic Neoplasm	Phase 2	Completed	-	-
NCT00631462	Myelofibrosis	Phase 1	Completed	-	United States, California ... 展开 >> UCSD Moores Cancer Center San Diego, California, United States, 92093 Stanford Comprehensive Cancer Center Stanford, California, United States, 94305 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Minnesota Mayo Clinic, Rochester Rochester, Minnesota, United States, 55905 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03755518	Primary Myelofibrosis ... 展开 >> Thrombocytosis 收起 <<	Phase 3	Not yet recruiting	October 31, 2022	-

Fedratinib {[allProObj[0].p_purity_real_show]}

Fedratinib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Fedratinib 质控信息

Fedratinib 生物活性

Fedratinib 细胞研究

Fedratinib 动物研究

Fedratinib 临床研究

Fedratinib 参考文献

Fedratinib 实验方案

Fedratinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Fedratinib {[allProObj[0].p_purity_real_show]}

Fedratinib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Fedratinib 质控信息

Fedratinib 生物活性

Fedratinib 细胞研究

Fedratinib 动物研究

Fedratinib 临床研究

Fedratinib 参考文献

Fedratinib 实验方案

Fedratinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Fedratinib 纯度/质量文件产品仅供科研